The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice and β3-AR Knock-Out Mice
Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM
Endocrinology (2001)
Both hGH and AOD-9604 upregulated β3-adrenergic-receptor expression and produced weight loss in obese wild-type mice, but neither compound sustained those effects in β3-AR knockout animals — the experiment that localised AOD-9604's lipolytic mechanism to the β3 channel.
This is the β3-adrenergic-receptor knockout paper that anchors the mechanistic story for AOD-9604. Published in Endocrinology in 2001 by Heffernan and the Monash University group (with the Summers pharmacology laboratory contributing the β3-AR genetic-deficiency expertise), the paper tests whether the lipolytic effects of AOD-9604 and full-length human growth hormone require an intact β3-adrenergic-receptor signal in adipose tissue. The design is the standard genetic-knockout dissection: parallel chronic dosing of obese wild-type and β3-AR-null mice with hGH or AOD-9604, with body-weight, adipose-mass, and β3-AR-expression endpoints.
The findings have three load-bearing parts. First, 14 days of treatment with either hGH or AOD-9604 in obese wild-type mice reduced body weight and adipose mass and increased β3-adrenergic-receptor mRNA expression in white adipose tissue — both compounds upregulated the receptor that mediates catecholamine-driven lipolysis in rodents. Second, in β3-AR knockout mice, neither compound sustained the chronic weight-loss or lipolysis effect that was clearly present in wild-type animals; the genetic deletion of the β3 receptor abolished the chronic-dosing phenotype. Third, acute (single-dose) energy-expenditure effects of the compounds were preserved in knockouts, suggesting that the immediate metabolic response operates through additional channels but that the sustained weight-loss phenotype requires β3-AR signaling downstream. The authors concluded that the β3-adrenergic pathway is the load-bearing downstream effector of both hGH's and AOD-9604's chronic lipolytic action — and that the two compounds operate through indirect upregulation of the receptor rather than direct β3-AR binding.
The paper is the second pillar of the mechanistic case for AOD-9604 together with Ng et al. 2000. The β3-AR localisation is the basis for the marketing-literature claim that AOD-9604 acts through a fundamentally different pathway than full-length hGH — a claim that is mechanistically supported here but says nothing about whether the rodent lipolysis signal translates into clinically meaningful human weight loss.
The β3-adrenergic receptor's role in fat metabolism differs substantially between rodents and humans. The murine β3-AR is expressed at high density in white adipose tissue and is the dominant adrenergic regulator of rodent lipolysis; the human β3-AR is far less abundantly expressed in adult adipocytes and the β1 and β2 isoforms dominate human lipolytic regulation. The clinical-development history of selective β3-AR agonists (CL-316,243, mirabegron, solabegron) in human obesity has been characterised by exactly this translation failure — robust rodent thermogenesis and weight loss that has not reproduced in human trials. The Heffernan paper localises AOD-9604's mechanism cleanly in mice; the relevance of that localisation to humans is exactly the question the subsequent Metabolic Pharmaceuticals Phase IIb trial was designed to answer, and the answer was negative. The replication caveat that applies to the Ng 2000 paper applies here as well: the Monash group authored most of the AOD-9604 preclinical literature, and the β3-AR-dependence finding has not been independently reproduced by an unaffiliated laboratory at scale. The Stier 2013 integrated safety summary and the /peptides/aod-9604 page treat this mechanism work as preclinical rationale that did not translate at the Phase IIb scale.
07·Member discussion
No member discussion yet.
Member-only conversation lives here — cycle notes, practitioner commentary, pattern-matching. Be the first paying member to start the thread.